CHICAGO — For patients diagnosed with high-risk prostate cancer that has not metastasized, two main treatment options are typically considered: surgical removal of the prostate or a combination of radiation and hormone therapies. However, new insights from a phase 3 clinical trial suggest that a third option might soon become available. This new approach involves administering hormone therapy both before and after surgical removal of the prostate.
The PROTEUS trial revealed that using two hormone therapies before and after surgery outperformed the use of only one hormone therapy in patients with high-risk, early-stage prostate cancer.
The findings have sparked varied interpretations among prostate cancer specialists. Many experts told STAT that the trial’s results could redefine the standard of care for these patients. Emmanual Antonarakis, a genitourinary medical oncologist at the University of Minnesota, described the trial’s outcome as a “watershed moment” for prostate cancer treatment, as noted in an editorial in the New England Journal of Medicine editorial.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
Already have an account? Log in
View All Plans
To read the rest of this story subscribe to STAT+.
Subscribe
